StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Down 1.9 %
Shares of NASDAQ:PULM opened at $2.11 on Wednesday. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The firm has a 50-day simple moving average of $2.09 and a 200 day simple moving average of $2.01. The company has a market cap of $7.70 million, a PE ratio of -0.71 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Calculate Inflation Rate
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Golden Cross Stocks: Pattern, Examples and Charts
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
